Women's Health Weekly
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Women's Health Weekly
We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.
Business & Finance
Cancer-focused pharmaceutical company signs agreement for $25.5 million sale of stock
March 9th, 2006
Tapestry Pharmaceuticals, Inc. (TPPH) announced that it has entered into definitive agreements with a number of institutional investors, led by Special Situations Funds, Tang Capital Partners, LP, and Baker Brothers Investments for the sale of $25.5 million of the company's common stock and warrants. The financing will support Tapestry's ongoing clinical development of TPI 287, a third generation taxane, which is currently in two phase 1 clinical trials in the United States and overseas to determine the safety and pharmacokinetic profile of the compound. In conjunction with this financing, Tapestry announced that its board of directors has approved a...
Source: Women's Health Weekly (2006-03-09)
|
